In Vitro Activity of Solithromycin against Erythromycin-Resistant Streptococcus agalactiae
Open Access
- 1 March 2014
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (3) , 1693-1698
Abstract
The in vitro antibacterial activity of solithromycin (CEM-101) against macrolide-resistant isolates ( n = 62) of Streptococcus agalactiae (group B streptococcus [GBS]) was determined. Phenotypic characterization of macrolide-resistant strains was performed by double-disc diffusion testing. A multiplex PCR was used to identify the erm (B), erm (TR), and mef (A/E) genes, capsular genotypes, and alpha-like (Alp) protein genes from the GBS strains. Determination of MIC was carried out using the microdilution broth method. The Etest method was used for penicillin, azithromycin, clarithromycin, and erythromycin. Solithromycin had a MIC 50 of ≤0.008 μg/ml and a MIC 90 of 0.015 μg/ml against macrolide-susceptible S. agalactiae . These MICs were lower than those displayed by penicillin (MIC 50 of 0.032 μg/ml and MIC 90 of 0.047 μg/ml), the antibiotic agent of choice for prophylaxis and treatment of GBS infections. Against macrolide-resistant S. agalactiae , solithromycin had a MIC 50 of 0.03 μg/ml and a MIC 90 of 0.125 μg/ml. Against erm (B) strains, solithromycin had a MIC 50 of 0.03 μg/ml and a MIC 90 of 0.06 μg/ml, while against mef (A) strains, it had a MIC 50 of 0.03 μg/ml and a MIC 90 of 0.125 μg/ml. Most erythromycin-resistant GBS strains were of serotype V (64.5%) and associated significantly with alp2-3 . Moreover, a statistically significant association was observed between the constitutive macrolide-lincosamide-streptogramin B resistance (cMLS B ) phenotype and the erm (B) gene-carrying strains, the alp2-3 gene and the M phenotype, and the mef (A/E) gene and epsilon . Overall, our results show that solithromycin had lower or similar MICs than penicillin and potent activity against macrolide-resistant strains independent of their genotype or phenotype, representing a valid therapeutic alternative where β-lactams cannot be used.Keywords
This publication has 31 references indexed in Scilit:
- CEM-101 Activity against Gram-Positive OrganismsAntimicrobial Agents and Chemotherapy, 2010
- A multiplex PCR assay for the direct identification of the capsular type (Ia to IX) of Streptococcus agalactiaeJournal of Microbiological Methods, 2010
- In Vitro Activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with Defined Macrolide Resistance MechanismsAntimicrobial Agents and Chemotherapy, 2010
- Molecular characterization and antimicrobial susceptibility profiles inStreptococcus agalactiaecolonizing strains: association of erythromycin resistance with subtype III-1 genetic clone familyClinical Microbiology and Infection, 2009
- Telithromycin‐associated hepatotoxicityHepatology, 2009
- Genetic Heterogeneity in pbp Genes among Clinically Isolated Group B Streptococci with Reduced Penicillin SusceptibilityAntimicrobial Agents and Chemotherapy, 2008
- Point Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to β-Lactam AntibioticsAntimicrobial Agents and Chemotherapy, 2008
- First Molecular Characterization of Group B Streptococci with Reduced Penicillin SusceptibilityAntimicrobial Agents and Chemotherapy, 2008
- Molecular Epidemiology and Distribution of Serotypes, Surface Proteins, and Antibiotic Resistance among Group B Streptococci in ItalyJournal of Clinical Microbiology, 2007
- Erythromycin and Clindamycin Resistance in Group B Streptococcal Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2006